Skip to main content

Advertisement

SpringerLink
Log in

Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis

  • Review
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Accumulative evidences have underpinned the nature candidates from Chinese medicine (CM), particularly CM served as blood activating and stasis resolving (BASR, Huoxue Huayu in Chinese) by targeting tumor-associated angiogenesis. However, recent experiment research on the therapeutic angiogenesis by BASR-CM attracts wide attention and discussion. This opinion review focused on the underlying link between two indications and anticipated that (1) BASR-CM might emphasize on a balanced multi-cytokines network interaction; (2) BASR-CM might address on the nature of diseases prior to differently affecting physiological and pathological angiogenesis; (3) BASR-CM might mainly act on perivascular cells, either promotes arteriogenesis by increasing arteriogenic factors in ischemic diseases, or simultaneously keep a quiescent vasculature to impede angiogenesis in tumor context.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.

    Article  CAS  PubMed  Google Scholar 

  2. Samant RS, Shevde LA. Recent advances in antiangiogenic therapy of cancer. Oncotarget 2011;2:122–134.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010;102:S2–S9.

    Article  PubMed  PubMed Central  Google Scholar 

  4. World Health Organization. WHO international standard terminologies on traditional medicine in the Western Pacific region. Geneva, Switzerland. World Health Organization 2007.

  5. Chen ZX, Liu XQ, Gao WY, Liu CX. Studies on pharmacology, toxicology and pharmacokinetics of the chemical constituents in hemorrheologic agent. Asia J Pharmacokinet Pharmacodyn 2008;8:15–30.

    Google Scholar 

  6. Chang MY, ed. Applied classical and empirical anticancer prescriptions. Beijing: China Medical Science Press;1996.

  7. Qian YF, Wang XJ. Effects of blood-activating and stasisresolving drugs on tumor formation and metastasis. J Tradit Chin Med 2009;29:301–310.

    Article  PubMed  Google Scholar 

  8. Lu X, Li B. Exploration of the effect and mechanism of activating blood circulation and stasis-removing therapy on tumor metastasis. Chin J Integr Med 2009;15:395–400.

    Article  CAS  PubMed  Google Scholar 

  9. Xi S, Zhang Q, Xie H, Liu L, Liu C, Gao X, et al. Effects of hydroxy safflor yellow A on blood vessel and mRNA expression with VEGF and bFGF of transplantation tumor with gastric adenocarcinoma cell line BGC-823 in nude mice. Chin J Chin Mater Med (Chin) 2009;34:605–610.

    CAS  Google Scholar 

  10. Zhang LJ, Chen L, Lu Y, Wu JM, Xu B, Sun ZG, et al. Danshensu has anti-tumor activity in B16F10 melanoma by inhibiting angiogenesis and tumor cell invasion. Eur J Pharmacol 2010;643:195–201.

    Article  CAS  PubMed  Google Scholar 

  11. Kim SA, Lee HJ, Ahn KS, Lee HJ, Lee EO, Ahn KS, et al. Paeonol exerts anti-angiogenic and anti-metastatic activities through downmodulation of Akt activation and inactivation of matrix metalloproteinases. Biol Pharm Bull 2009;32:1142–1147.

    Article  CAS  PubMed  Google Scholar 

  12. Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR, et al. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 2006;15:1557–1562.

    CAS  PubMed  Google Scholar 

  13. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 2007;13:3423–3430.

    Article  CAS  PubMed  Google Scholar 

  14. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, et al. Acetyl- 11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 2009;69:5893–5900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chen W, Lu Y, Wu J, Gao M, Wang A, Xu B. Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis. Cancer Chemother Pharmacol 2012;67:799–808.

    Article  Google Scholar 

  16. Chen YJ, Tsai YM, Kuo CD, Ku KL, Shie HS, Liao HF. Norcantharidin is a small-molecule synthetic compound with anti-angiogenesis effect. Life Sci 2009;85:642–651.

    Article  CAS  PubMed  Google Scholar 

  17. Chen L, Lu Y, Wu JM, Xu B, Zhang LJ, Gao M, et al. Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by vascular endothelial growth factor. Biochem Biophys Res Commun 2009;86:374–379.

    Article  Google Scholar 

  18. Yeh JC, Cindrova-Davies T, Belleri M, Morbidelli L, Miller N, Cho CW, et al. The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis 2011;14:187–197.

    Article  CAS  PubMed  Google Scholar 

  19. Zhang W, Lu Y, Xu B, Wu J, Zhang L, Gao M, et al. Acidic mucopolysaccharide from Holothuria leucospilota has antitumor effect by inhibiting angiogenesis and tumor cell invasion in vivo and in vivo. Cancer Biol Ther 2009;8:1489–1499.

    Article  CAS  PubMed  Google Scholar 

  20. Komi Y, Suzuki Y, Shimamura M, Kajimoto S, Nakajo S, Masuda M, et al. Mechanism of inhibition of tumor angiogenesis by beta-hydroxyisovalerylshikonin. Cancer Sci 2009;100:269–277.

    Article  CAS  PubMed  Google Scholar 

  21. Bian W, Chen F, Bai L, Zhang P, Qin W. Dihydrotanshinone inhibits angiogenesis both in vivo and in vivo. Acta Biochim Biophys Sin 2008;40:1–6.

    Article  CAS  PubMed  Google Scholar 

  22. Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, Lee HC, et al. Emodin inhibits vascular endothelial growth factor-Ainduced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 2006;118:2711–2720.

    Article  CAS  PubMed  Google Scholar 

  23. Liu J, Chen Z. Traditional Chinese medicine in the new century. Front Med 2011;5:111–114.

    Article  PubMed  Google Scholar 

  24. Wu ZG. Therapeutic angiogenesis: the combination point of Chinese and Western medicine in prevention and treatment of ischemic heart disease. Chin J Integr Med 2009;15:323–324.

    Article  PubMed  Google Scholar 

  25. Höckel M, Schlenger K, Doctrow S, Kissel T, Vaupel P. Therap eutic angiogenesis. Arch Surg 1993;128:423–439.

    Article  PubMed  Google Scholar 

  26. Li JH, Wu YL, Ye JH, Ning YG, Yu HY, Peng ZJ, et al. Effects of blood-activating and stasis-removing drugs combined with VEGF gene transfer on angiogenesis in ischemic necrosis of the femoral head. J Tradit Chin Med 2009;29:216–219.

    Article  PubMed  Google Scholar 

  27. Zhu HF, Wan D, Luo Y, Zhou JL, Chen L, Xu XY. Catalpol increases brain angiogenesis and up-regulates VEGF and EPO in the rat after permanent middle cerebral artery occlusion. Int J Biol Sci 2010;6:443–453.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lin CM, Chiu JH, Wu IH, Wang BW, Pan CM, Chen YH. Ferulic acid augments angiogenesis via VEGF, PDGF and HIF-1 alpha. J Nutr Biochem 2010;21:c627–c633.

    Article  Google Scholar 

  29. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009;100:865–869.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in nonsmall cell lung cancer. Clin Cancer Res 2007;13:6649–6657.

    Article  CAS  PubMed  Google Scholar 

  31. Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010;87:262–271.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505–514.

    Article  CAS  PubMed  Google Scholar 

  33. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437–447.

    Article  CAS  PubMed  Google Scholar 

  34. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039–2049.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Messmer-Blust A, An X, Li J. Hypoxia-regulated angiogenic inhibitors. Trends Cardiovasc Med 2009;19:252–256.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Parekh HS, Liu G, Wei MQ. A new d awn for the use of traditional Chinese medicine in cancer therapy. Mol Cancer 2009;8:21.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 2007;3:211–268.

    Google Scholar 

  38. Heil M, Eitenmüller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006;10:45–55.

    Article  CAS  PubMed  Google Scholar 

  39. Cao Y. Therapeutic angiogenesis for ischemic disorders: what is missing for clinical benefits? Discov Med 2010;9:179–184.

  40. Wu P, Dugoua JJ, Eyawo O, Mills EJ. Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res 2009;28:112.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China

    Li Tao  (陶 丽), Sheng Wang  (王 生), Yang Zhao  (赵 杨), Ai-yun Wang  (王爱云), Yu-ping Liu  (刘玉萍), Yao Li  (李 尧), Zhi-qiang Yue  (岳志强), Wen-xing Chen  (陈文星) & Yin Lu  (陆 茵)

  2. Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, 210023, China

    Ai-yun Wang  (王爱云), Wen-xing Chen  (陈文星) & Yin Lu  (陆 茵)

  3. Department of Pharmacy, Provincial Hospital Affiliated to Anhui Medical University, Hefei, 230001, China

    Lei Zhang  (张 蕾)

  4. Fujian Provincial Hospital, Clinical College of Fujian Medical University, Fuzhou, 350001, China

    Jun-shan Ruan  (阮君山)

  5. Department of Pharmacology, Hanlin College, Nanjing University of Chinese Medicine, Taizhou Jiangsu Province, 225300, China

    Fang-tian Fan  (范方田)

  6. Department of Pharmaceutics, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China

    Wen-hui Qian  (钱文慧)

Authors
  1. Li Tao  (陶 丽)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheng Wang  (王 生)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yang Zhao  (赵 杨)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ai-yun Wang  (王爱云)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lei Zhang  (张 蕾)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun-shan Ruan  (阮君山)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fang-tian Fan  (范方田)
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yu-ping Liu  (刘玉萍)
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yao Li  (李 尧)
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zhi-qiang Yue  (岳志强)
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wen-hui Qian  (钱文慧)
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Wen-xing Chen  (陈文星)
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yin Lu  (陆 茵)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yin Lu  (陆 茵).

Additional information

Supported by the National Natural Science Foundation of China (Nos. 81173174, 81403260 and 81573859), China Post-doctoral Science Foundation (No. 2014M551639), Natural Science Foundation of Jiangsu Province (No. BK2012854), Postdoctoral Funding in Jiangsu Province (No. 1401138C), 2013 Program for Excellent Scientific and Technological Innovation Team of Jiangsu Higher Education (No. PPZY2015A070), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and Jiangsu College Graduate Research and Innovation Projects (No. CXZZ13_0627)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tao, L., Wang, S., Zhao, Y. et al. Pleiotropic effects of herbs characterized with blood-activating and stasis-resolving functions on angiogenesis. Chin. J. Integr. Med. 22, 795–800 (2016). https://doi.org/10.1007/s11655-015-2405-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-015-2405-x

Keywords

Search

Navigation